Lately, the interest in the application of nanomaterials in the medicinal field has significantly increased; carbon nanotubes and metallic or polymeric nanoparticles are under investigation as recent results showed an important improvement in the drug transportation linked to solubility, biodisponibility, immunocompatibility and cytotoxicity.
It is in this context that various nanoformulations have been proved to ameliorate the effectivity of an important number of drugs, reducing the effective dose needed and therefore the adverse side reactions. The different applications of such nanostructures could include their use as excipients in the formulation, as supports by functionalization and as encapsulations of the drugs.
Synthelia is now engaged in this field with the objective of investigating how to generate and functionalise these nonoparticles, with the aim of understanding its behaviour in cell cultures and animal models for the disease under study including cancer.
Synthelia and IMDEA Nanociencia have joined together to maximise the development of this technology in GMP production, ensuring the quality required for these standards. This alliance is under the technical direction of Dr. Álvaro Somoza (http://www.nanobioimdea.com/home/people/alvaro), a well-recognised international specialist in the field of nanomedicine for the development of several modified nanoparticles with bioactive compounds used in the treatment of diseases. In addition, this collaboration has been reinforced with the support of the “Comunidad de Madrid” with the award of an industrial Ph.D. grant for a period of three years.